Cas no 102625-70-7 (Pantoprazole)

Pantoprazole structure
Pantoprazole structure
Product Name:Pantoprazole
CAS No:102625-70-7
MF:C16H15F2N3O4S
MW:383.369809389114
MDL:MFCD00870182
CID:62308
PubChem ID:4679
Update Time:2025-07-21

Pantoprazole Chemical and Physical Properties

Names and Identifiers

    • Pantoprazole
    • 5-(DIFLUOROMETHOXY)-2-[[(3,4-DIMETHOXY-2-PYRIDINYL)METHYL]SULFINYL]-1H-BENZIMIDAZOLE
    • 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1h-benzimidazole
    • Pantoprazole&amp
    • Int.
    • 5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-3H-benzoimidazole
    • (3,4-dimethoxy-2-pyridinyl)methyl 5-methyl-1H-1,3-benzimidazol-2-yl sulfoxide
    • BY-1023
    • SKF-96022
    • [(3,4-Dimethoxypyridin-2-yl)methyl][5-(difluoromethoxy)-1H-benzimidazol-2-yl] sulfoxide
    • 5-(Difluoromethoxy)-1H-benzimidazole-2-yl(3,4-dimethoxy-2-pyridylmethyl) sulfoxide
    • Pantoprazole sodium
    • SKF96022
    • [14C]-Pantoprazole
    • 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyriainyl)methyl]sulfinyl]-1H-benzimidazole
    • 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
    • 5-difluorom
    • 5-difluoromethoxy-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
    • 5-difluoromethoxy-2-[(3,4-dimethoxy-pyridin-2-yl)methylsulfinyl]-1H-benzimidazole
    • Pantoloc
    • Pantoprazol
    • Pantoprazolum
    • Pantoprazolum [INN-Latin]
    • Pantozol
    • Patoprazole
    • Protonix
    • Pantoprazole&Int.
    • Pantoprazole (Protonix)
    • PANTOPRAZOLE SODIUM 98-102%
    • Pantoprazole (base and/or unspecified salts)
    • 5-(difluoMethoxyl)-2-{[(3,4-diMethoxyl-2-pyridy
    • Tox21_111477_1
    • BRD-A22380646-001-01-5
    • (R)-(+)-Pantoprazole;(+)-(R)-Pantoprazole;Pantoprazole Isomer(R) Impurity
    • MFCD00870182
    • Pantoprazole (USAN/INN)
    • 5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)
    • (R)-6-(Difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
    • Pantecta Control
    • Pantoprazol [INN-Spanish]
    • (+)-(R)-Pantoprazole
    • NSC-759257
    • CS-3161
    • FT-0602547
    • DTXCID803416
    • Panyocid
    • D05353
    • Pantoprazole [USAN:INN:BAN]
    • EN300-19767202
    • BY1023
    • SR-01000763715
    • PANTOPRAZOLE [HSDB]
    • MLS003882559
    • PANTOPRAZOLE [MI]
    • PANTOPRAZOLE [VANDF]
    • NSC759257
    • 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole
    • DTXSID4023416
    • NCGC00095188-02
    • Pantozol Control
    • apo-Pantoprazole
    • SCHEMBL29465
    • DB00213
    • BRD-A22380646-001-02-3
    • NCGC00095188-04
    • BCP21400
    • 6-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methane]sulfinyl}-1H-1,3-benzodiazole
    • NCGC00095188-03
    • (R)-(+)-Pantoprazole;R-enantiomer of Pantoprazole;(R)-Pantoprazole;5-(Difluoromethoxy)-2-[(R)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole ;5-(Difluoromethoxy)-2-[(R)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole. - See more at: https://www.clearsynth.com/en/CST38666.html#sthash.yGNPTXpx.dpuf
    • (R)-Pantoprazole
    • NCGC00095188-01
    • HSDB 7292
    • Altopan
    • PANTOPRAZOLE (MART.)
    • SBI-0206873.P001
    • CHEBI:7915
    • A901011
    • Controloc Control
    • SMR002533625
    • CCG-268437
    • SK&F-96022
    • 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-
    • BS-14224
    • GTPL7260
    • EC 600-331-6
    • 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
    • D8TST4O562
    • 164579-32-2
    • PANTOPRAZOLE [WHO-DD]
    • s2105
    • BDBM50241342
    • PANTOPRAZOLE [MART.]
    • (S)-Pantoprazole
    • 1H-BENZIMIDAZOLE, 5-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDYL)METHYL)SULFINYL)-
    • CHEMBL1502
    • BCP20279
    • Somac Control
    • HMS1922H20
    • AKOS034831879
    • Pantoloc Control
    • AKOS015894910
    • Q286846
    • AB01275513_02
    • 5-Difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
    • 5-(Difluoromethoxy)-2-
    • 2-(((3,4-DIMETHOXYPYRIDIN-2-YL)METHYL)SULFINYL)-5-DIFLUOROMETHOXY-1H-BENZIMIDAZOLE
    • AB01275513-01
    • SK&F 96022
    • SPECTRUM1505818
    • AC-679
    • 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
    • SR-01000763715-3
    • 6-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
    • NSC 759257
    • 5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1H-benzimidazole
    • CAS-102625-70-7
    • PANTOPRAZOLE [EMA EPAR]
    • P2262
    • BY 1023
    • NCGC00095188-05
    • PANTOPRAZOLE [USAN]
    • PANTOPRAZOLE [INN]
    • Zovanta
    • (+/-)-PANTOPRAZOLE
    • Pharmakon1600-01505818
    • 5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole
    • NS00000297
    • 102625-70-7
    • Pantoprazol (INN-Spanish)
    • BSPBio_002320
    • 6-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole
    • 6-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
    • BIDD:GT0003
    • HMS2093F14
    • A02BC02
    • 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole
    • 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole
    • 5-Difluoromethoxy-2-(3,4-dimethoxy-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole
    • A800593
    • 2-(((3,4-Dimethoxy-2-pyridinyl)methyl)-sulfinyl)-5-methyl-1H-1,3-benzimidazole
    • UNII-D8TST4O562
    • J-000744
    • 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]benzimidazole
    • CCG-213558
    • (S)-6-(Difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
    • HY-17507
    • Tox21_111477
    • Pantoprazole sodium hydrate
    • Protonix I.V.
    • HMS2090H03
    • 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole
    • Pantoprazolum (INN-Latin)
    • SB17368
    • NCGC00389443-01
    • SK-96022
    • BRD-A22380646-236-06-6
    • G60931
    • STL451032
    • BRD-A22380646-001-05-6
    • BRD-A22380646-236-05-8
    • NCGC00095188-08
    • MDL: MFCD00870182
    • Inchi: 1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
    • InChI Key: IQPSEEYGBUAQFF-UHFFFAOYSA-N
    • SMILES: S(CC1C(=C(C=CN=1)OC)OC)(C1=NC2C=CC(=CC=2N1)OC(F)F)=O

Computed Properties

  • Exact Mass: 383.07500
  • Monoisotopic Mass: 383.075133
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 7
  • Heavy Atom Count: 26
  • Rotatable Bond Count: 7
  • Complexity: 490
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 1
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 106
  • Surface Charge: 0
  • Tautomer Count: 2
  • XLogP3: 2.4

Experimental Properties

  • Color/Form: Quasi white solid
  • Density: 1.51
  • Melting Point: 139-140° (dec)
  • Boiling Point: 586.9 °C at 760 mmHg
  • Flash Point: 308.7 °C
  • Refractive Index: 1.642
  • PSA: 105.54000
  • LogP: 3.75000
  • pka: pKa1 3.92; pKa2 8.19(at 25℃)

Pantoprazole Security Information

Pantoprazole Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
S e l l e c k ZHONG GUO
S2105-100mg
Pantoprazole
102625-70-7 99.94%
100mg
¥794.97 2023-09-15
S e l l e c k ZHONG GUO
S2105-500mg
Pantoprazole
102625-70-7 99.94%
500mg
¥2433.32 2023-09-15
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
P302094-1g
Pantoprazole
102625-70-7 97%
1g
¥871.90 2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
P302094-100mg
Pantoprazole
102625-70-7 97%
100mg
¥435.00 2021-05-25
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
P302094-5g
Pantoprazole
102625-70-7 97%
5g
¥3136.90 2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
P302094-500mg
Pantoprazole
102625-70-7 97%
500mg
¥1,327.00 2021-05-25
DC Chemicals
DC9876-100 mg
Pantoprazole
102625-70-7 >98%
100mg
$100.0 2022-02-28
DC Chemicals
DC9876-250 mg
Pantoprazole
102625-70-7 >98%
250mg
$200.0 2022-02-28
DC Chemicals
DC9876-1 g
Pantoprazole
102625-70-7 >98%
1g
$400.0 2022-02-28
TRC
P190003-100mg
Pantoprazole
102625-70-7
100mg
$ 52.00 2023-09-06

Pantoprazole Suppliers

Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:102625-70-7)Pantoprazole
Order Number:A800593
Stock Status:in Stock
Quantity:5g
Purity:99%
Pricing Information Last Updated:Friday, 30 August 2024 04:36
Price ($):391.0
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:102625-70-7)Pantoprazole
Order Number:LE9625
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:01
Price ($):discuss personally

Additional information on Pantoprazole

Recent Advances in Pantoprazole (102625-70-7) Research: A Comprehensive Review

Pantoprazole (CAS: 102625-70-7), a proton pump inhibitor (PPI), has been widely used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Recent studies have focused on its pharmacological mechanisms, clinical efficacy, and potential new applications. This review synthesizes the latest findings from peer-reviewed journals, clinical trials, and industry reports to provide a comprehensive update on Pantoprazole research.

One of the key areas of recent investigation is the molecular mechanism of Pantoprazole's action. Studies have elucidated its binding affinity to the H+/K+-ATPase enzyme in gastric parietal cells, leading to prolonged inhibition of gastric acid secretion. Advanced crystallography and molecular docking simulations have provided deeper insights into the structural interactions between Pantoprazole and its target, which may inform the development of next-generation PPIs with improved efficacy and reduced side effects.

Clinical research has also explored the comparative effectiveness of Pantoprazole versus other PPIs. A 2023 meta-analysis of randomized controlled trials demonstrated that Pantoprazole exhibits comparable efficacy to omeprazole and esomeprazole in acid suppression but with a more favorable safety profile, particularly in long-term use. These findings support its continued preference in specific patient populations, such as the elderly and those with renal impairment.

Emerging applications of Pantoprazole beyond its traditional uses have been a significant focus. Preclinical studies suggest potential anti-inflammatory and antioxidant properties, which could expand its therapeutic scope. For instance, recent in vitro and animal models indicate that Pantoprazole may modulate cytokine production and reduce oxidative stress, opening avenues for research in conditions like inflammatory bowel disease and even certain cancers.

Pharmacokinetic studies have further refined our understanding of Pantoprazole's metabolism, particularly the role of CYP2C19 polymorphisms in its variability among individuals. New formulations, including delayed-release tablets and intravenous preparations, have been developed to enhance bioavailability and patient compliance, addressing some of the limitations observed in earlier versions of the drug.

In conclusion, Pantoprazole (102625-70-7) remains a cornerstone in acid-related disorder management, with ongoing research uncovering new dimensions of its pharmacology and therapeutic potential. Future directions may include personalized medicine approaches based on genetic profiling and the exploration of its pleiotropic effects in non-GI indications. This evolving body of knowledge underscores the importance of continued investment in Pantoprazole-related research to optimize its clinical utility.

Recommended suppliers
Amadis Chemical Company Limited
(CAS:102625-70-7)Pantoprazole
A800593
Purity:99%
Quantity:5g
Price ($):391.0
Email
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:102625-70-7)Pantoprazole
LE9625
Purity:99%
Quantity:25KG,200KG,1000KG
Price ($):Inquiry
Email